Linked from

The 19 pages that link to Drug resistance, each with the reason it gives.

• ChemotherapyRelated: Cancer cells can acquire or select traits that make chemotherapy less effective.

• Mass drug administrationRelated: Repeated population-wide exposure can select for resistant organisms or parasites.

• ArtemisininNarrower topic: Artemisinin resistance is one instance of the broader threat to antimicrobial treatment.

• Targeted therapyRelated: Tumors and pathogens can adapt around the pathway a drug blocks.

• Acute myeloid leukemiaRelated: Resistance to chemotherapy and targeted drugs remains a major cause of AML treatment failure.

• Hepatocellular carcinomaRelated: Resistance can limit the durability of targeted and immune-based treatments.

• Acute lymphoblastic leukemiaRelated: Therapy-resistant leukemia cells can persist and drive treatment failure or relapse.

• AntimicrobialNarrower topic: Antimicrobial resistance belongs to the broader phenomenon of resistance to drugs.

• Clonal evolutionRelated: Treatment can favor resistant clones already present or arising during therapy.

• OncologyRelated: Cancer cells can evolve resistance that limits the duration of treatment benefit.

• TrastuzumabRelated: Some HER2-positive tumors eventually progress despite trastuzumab.

• Cancer researchRelated: It drives research into relapse and therapies that remain effective over time.

• ImatinibNarrower topic: Resistance to imatinib can arise through target mutations, altered drug exposure, or clonal evolution.

• DoxorubicinNarrower topic: Tumors can become less responsive through drug export, altered targets, or enhanced DNA repair.

• KinetoplastidRelated: Resistance threatens therapies for kinetoplastid diseases and can arise through varied mechanisms.

• NiclosamideRelated: Repeated antiparasitic use makes monitoring reduced susceptibility relevant to niclosamide’s long-term utility.

• Satoshi ŌmuraRelated: Extensive ivermectin use makes monitoring parasite susceptibility important.

• DaunorubicinRelated: Efflux pumps and altered drug targets can reduce leukemia cells’ response to daunorubicin.

• Tenofovir disoproxilRelated: HIV and hepatitis B mutations can reduce susceptibility to tenofovir-based treatment.